(Q87215586)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

main subject

phase III clinical trial

1 reference

1 reference

1 reference

1 reference

1 reference

11

Ignace Vergote

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

4

Giovanni Scambia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Scott McMeekin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Don Dizon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

James Barter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Lyudmila Manzyuk

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Alla Lisyanskaya

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ana Oaknin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sarah Ringuette

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Pralay Mukhopadhyay

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Julie Rosenberg

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

26 April 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

18-23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.04.026

10.1016/J.YGYNO.2015.04.026

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925990%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference